Paul E. DiCorleto, Ph.D., is the Chair of the Lerner Research Institute of the Cleveland Clinic and Chair, Department of Molecular Medicine, Case Western Reserve University School of Medicine. The Lerner Research Institute (LRI) is home to over 180 principal investigators and 1500 total employees performing biomedical research that ranges from cellular and molecular biology to biomedical engineering. The LRI is also home to the Center for Clinical Research, which provides infrastructure support and oversight for all human subjects research at the Cleveland Clinic. Research funding from external sources to the LRI exceeded $165 million in 2008 with over $100 million coming from the National Institutes of Health (NIH) and other Federal agencies.
Dr. DiCorleto received his undergraduate training in chemistry at Rensselaer Polytechnic Institute and his doctorate in biochemistry from Cornell University. Dr. DiCorleto’s research focuses on the molecular and cellular basis of atherosclerosis. He has been with the Cleveland Clinic since 1982, having served previously as Chairman of the Department of Cell Biology and as an Associate Chief of Staff. He is currently a member of the Clinic’s Board of Governors and Board of Trustees.
On a national level, Dr. DiCorleto has chaired multiple NIH and American Heart Association review panels, as well as several national conferences on research into heart and vascular disease. He has published over 100 articles in his field and serves on the editorial board of multiple scientific journals. Dr. DiCorleto has served as President of the North American Vascular Biology Organization, and is currently a member of the Scientific Advisory Board. He also serves as a member of the Association of American Medical Colleges’ Advisory Panel on Research. He was elected a Fellow of the American Association for the Advancement of Science (AAAS) in 2007. Dr. DiCorleto is a Community Board member of the Cleveland State University Board of Trustees. He has served as a consultant and Board member of multiple companies and is currently a director of Cleveland BioLabs, Inc., a publicly traded company.